Phil Gutry Net Worth

Phil Gutry biography

Phil Gutry serves as Independent Director of the Company. Mr. Gutry has 20 years of experience in the biopharmaceutical industry in a variety of senior investment, business development, and strategic roles. Mr. Gutry currently serves as Chief Business Officer at Kronos Bio. He previously led oncology business development and strategy serving as Executive Director, Business Development at Regeneron Pharmaceuticals, Inc., an integrated biopharmaceutical company from July 2015 through October 2018. From May 2011 to June 2015, Mr. Gutry served as Principal at MPM Capital where he led new company formation and venture investments in oncology and neuroscience, and managed MPM's pharmaceutical partnerships with Janssen and Astellas. Prior to joining MPM Capital, Mr. Gutry worked in corporate development at Gilead Sciences, Inc., a research-based biopharmaceutical company, where he focused on M&A and licensing in oncology, respiratory, liver, and infectious diseases. Mr. Gutry previously worked at Riverside Partners, LLC, a health-care focused private equity firm, where he invested in commercial-stage life science companies. He began his career with The Wilkerson Group, a healthcare focused consulting firm. Mr. Gutry received his M.B.A. in Healthcare Management from The Wharton School and an A.B. in Earth Sciences from Dartmouth College. Our Board believes that Mr. Gutry’s experience in the biopharmaceutical industry makes him a valuable member of our Board.

What is the salary of Phil Gutry?

As the Independent Director of Cerecor Inc, the total compensation of Phil Gutry at Cerecor Inc is $96,917. There are 2 executives at Cerecor Inc getting paid more, with Joseph Miller having the highest compensation of $1,170,600.

How old is Phil Gutry?

Phil Gutry is 46, he's been the Independent Director of Cerecor Inc since 2015. There are 7 older and 2 younger executives at Cerecor Inc. The oldest executive at Cerecor Inc is Sol Barer, 72, who is the Chairman of the Board.

What's Phil Gutry's mailing address?

Phil's mailing address filed with the SEC is C/O CERECOR INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE, MD, 20850.

Insiders trading at Cerecor Inc

Over the last 9 years, insiders at Cerecor Inc have traded over $0 worth of Cerecor Inc stock and bought 18,463,844 units worth $43,946,959 . The most active insiders traders include Forest Baskett, Scott D Sandell и Capital, Llc Armistice Capi.... On average, Cerecor Inc executives and independent directors trade stock every 19 days with the average trade being worth of $601,142. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 16 August 2021, trading 50,000 units of CERC stock currently worth $138,000.

What does Cerecor Inc do?

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.

Cerecor Inc executives and stock owners

Cerecor Inc executives and other stock owners filed with the SEC include:

• Joseph Miller,
  Director
• Jamie Harrell,
  Chief Commercial Officer
• Phil Gutry,
  Independent Director
• Magnus Persson,
  Independent Director
• Gilla Kaplan,
  Independent Director
• Steven Boyd,
  Independent Director
• Suzanne Bruhn,
  Director
• Jeff Wilkins,
  Chief Development Officer
• Garry Neil,
  Chief Scientific Officer
• Christopher Sullivan,
  Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
• Michael Cola,
  Chief Executive Officer, Director
• Sol Barer,
  Chairman of the Board
• Thomas H Aasen,
  Director
• Mariam E Morris,
  Chief Financial Officer
• Ronald Marcus,
  Chief Medical Officer
• John Joseph Kaiser,
  Chief Business Officer
• Eugene A Bauer,
  Director
• Robert Jr. Moscato,
  Director
• Peter Greenleaf,
  Director
• Keith Schmidt,
  Director
• Pericles Calias,
  Chief Scientific Officer
• Matthew V Phillips,
  Chief Commercial Officer
• Randal Jones,
  Director
• Patrick J Crutcher,
  VP, Business Development
• Robert Jr.Lrs International...,
  
• Randal Fremantle, Llc Jones,
  
• Capital, Llc Boyd Steven Ar...,
  
• Simon Pedder,
  Executive Chairman of the Bd
• Uli Hacksell,
  Director
• Tree Partners Iv, L.P.Atp I...,
  
• David M Mott,
  10% owner
• Behshad Sheldon,
  Director
• Anthony A. Jr. Florence,
  10% owner
• Krishna Kittu Kolluri,
  10% owner
• Peter W. Sonsini,
  10% owner
• Harry R Weller,
  10% owner
• Blake M Paterson,
  CEO and President
• Forest Baskett,
  10% owner
• Ravi Viswanathan,
  10% owner
• M James Barrett,
  10% owner
• Scott D Sandell,
  10% owner
• Enterprise Associates 14, L...,
  
• Bioventures V, L.P.Mpm Asse...,
  
• Peter J Barris,
  10% owner
• Patrick J Kerins,
  10% owner
• Isaac Blech,
  Director
• James Archie Jr Harrell,
  Chief Commercial Officer
• Schond L. Greenway,
  CFO